Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026433 | 0.82 | MAPT (0.33) | MAPT | |
| SCHEMBL10110808 | 0.82 | MAPT (0.33) | MAPT | |
| SCHEMBL3681851 | 0.81 | MAPT (0.33) | MAPT | |
| SCHEMBL22883307 | 0.79 | MAPT (0.33) | MAPT | |
| SCHEMBL3371032 | 0.78 | MAPT (0.35) | MAPT | |
| SCHEMBL11419127 | 0.78 | MAPT (0.32) | MAPT | |
| SCHEMBL543811 | 0.78 | MAPT (0.35) | MAPT | |
| SCHEMBL3531184 | 0.76 | MAPT (0.34) | MAPT | |
| SCHEMBL3344614 | 0.76 | MAPT (0.37) | MAPT | |
| SCHEMBL18489636 | 0.76 | MAPT (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1617803-B1 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2010-09-22 | — | — | EP | disclosed |
| US-7468440-B2 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-23 | — | — | US | disclosed |
| US-20070213379-A1 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7230133-B2 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1617803-A4 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1617803-A2 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| WO-2004098512-A2 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235835-A1 | Malonamides and malonamide derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | MAPT 4455/4885 |
| US-20070213379-A1 | MALONAMIDES AND MALONAMIDE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, MAL2 | MAPT 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.